Parabilis Medicines sets biotech record with $670m IPO
Parabilis Medicines has secured the largest initial public offering (IPO) in biotech history, suggesting that an uptick of upsized public …
Post
-
-
Enhance clinical trial screening and improve patient matching accuracy
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to …
-
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact
As CEO of Coya Therapeutics, Dr Arun Swaminathan is steering the company’s lead programme, COYA 302, an immune-modulating combination designed …
-
Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement
Eli Lilly has inked a licensing deal worth up to $1bn with Swedish Alzheimer’s-focused biotech, AlzeCure – marking a continuation …
-
Aditxt and Ignite announce merger plans with strategic partner
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination …
-
MHRA to roll out new AI sandbox for medicines development
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans to launch a new AI sandbox to expedite …
-
Dangerous waters: Geopolitics, supply chains and access to medicines
Shortages of medicines for conditions such as diabetes, attention deficit hyperactivity disorder (ADHD) and hormone replacement therapy (HRT) have long …
-
Novo Nordisk puts AI at the centre of its clinical strategy
In the last few years, pharma leaders have been scrambling to see how artificial intelligence (AI) can augment every aspect …
-
WuXi AppTec hits back after being named in Pentagon’s Chinese military list
The Pentagon has judged that Wuxi AppTec qualifies as a Chinese military company, adding strain to already delicate ties between …
-
ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering
This year at the American Diabetes Association (ADA) Scientific Sessions, new Phase III data were presented evaluating the safety and …
-
ADA26: Early data for teplizumab demonstrates promise for slowing T1D progression
During the 2026 American Diabetes Association (ECO) Scientific Sessions in New Orleans, a real-world cohort of type 1 diabetic (T1D) …
-
GSK doubles down on oncology with $10.6bn Nuvalent takeover
GSK will acquire lung cancer biotech Nuvalent for $10.6bn in one of its largest ever deals, bolstering its pipeline with …
-
J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline
Johnson & Johnson (J&J) has agreed to purchase Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline …
-
Pfizer’s Hympavzi secures FDA expanded indications for haemophilia
Pfizer has received approval from the US Food and Drug Administration (FDA) for an expanded indication of Hympavzi (marstacimab-hncq) for …
-
Shift in biosimilar commercial landscape essential for sector sustainability, expert says
As the pharmacological treatment landscape continues to evolve, biologics are becoming increasingly incorporated into therapeutic regimens across a broad range …
